Finance

Lists
ACHV:NASDAQ
Achieve Life Sciences Inc
$7.08
+0.71%
(+0.050) 1D
Oct 7, 9:46:54 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACHV...
Open
$7.02
High
$7.12
Low
$6.96
Mkt. cap
752.45M
Avg. vol.
1.57M
Volume
48.98K
52-wk high
$8.64
52-wk low
$2.62
EPS
-$1.55
Beta
2.30
Shares outstanding
102.90M
No. of employees
28
Open
$7.02
High
$7.12
Low
$6.96
Mkt. cap
752.45M
Avg. vol.
1.57M
Volume
48.98K
52-wk high
$8.64
52-wk low
$2.62
EPS
-$1.55
Beta
2.30
Shares outstanding
102.90M
No. of employees
28
News stories
From web sources and news partners
About Achieve Life Sciences Inc
CEO-
Employees28
Founded1991
HeadquartersSeattle, Washington, United States
SectorBiotechnology
Websiteachievelifesciences.com
Analyst ratings
Based on 6 analysts giving stock ratings to ACHV in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ACHV in the last 3 months.
Highest
Current $7.08
$18.00 (+154.24%)
Average
$13.83 (+95.34%)
Lowest
$10.00 (+41.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Condulis
Stifel Nicolaus
Buy
Initiated
$18.00
+154.2%
09/30/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$17.00
+140.1%
09/03/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$10.00
+41.2%
08/12/2026
Maxwell Skor
Morgan Stanley
Buy
Initiated
$13.00
+83.6%
08/13/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
$13.00
+83.6%
08/12/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$12.00
+69.5%
08/11/2026
Ryan Deschner
Raymond James
Buy
Initiated
$20.00
+182.5%
06/26/2026
Mark Smith
Lake Street
Buy
Maintained
$11.00
+55.4%
05/13/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$20.00
+182.5%
05/12/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$13.00
+83.6%
04/20/2026
Thomas Flaten
Lake Street
Buy
Maintained
$11.00
+55.4%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.32M
3.87M
3.29M
3.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.37M
10.86M
7.17M
14.58M
Operating expense
14.69M
14.73M
10.46M
18.39M
Total operating expenses
14.69M
14.73M
10.46M
18.39M
Operating income
-14.69M
-14.73M
-10.46M
-18.39M
Other non operating income
-5.00K
7.00K
-13.00K
-57.48M
EBT including unusual items
-14.44M
-14.66M
-10.17M
-74.77M
EBT excluding unusual items
-14.34M
-14.55M
-10.45M
-74.67M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.44M
-14.66M
-10.17M
-74.77M
Net profit margin
-
-
-
-
Earnings per share
-0.28
-0.28
-0.19
-0.80
Interest and investment income
554.00K
427.00K
297.00K
1.48M
Interest expense
-192.00K
-251.00K
-274.00K
-277.00K
Net interest expenses
362.00K
176.00K
23.00K
1.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.64M
-14.67M
-10.41M
-18.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps